In its call for leadership change at HMA, Glenview accused the company of having "a deficiency at both the Board and management level."
In response to the SEC filing, HMA's board of directors issued a statement to shareholders rejecting the idea of instituting board members specially selected by Glenview.
"In our view, Glenview's actions are an unnecessary distraction to the Company's strategic review process and an attempt to advance its own agenda for the Company with its hand-picked nominees. … [O]ur focus is on serving the best interests of all stockholders over the narrow interests of one, as well as ensuring that we honor our commitment to provide our patients and communities with vital services of the highest quality. As you would expect, we are considering all strategic alternatives and opportunities available to the Company, including those alternatives suggested by Glenview."
"…[W]e strongly urge you to allow us to complete our work for the benefit of all stockholders, and to take no action in response to the Glenview materials until you hear from us about the results of our work so that you can make a fully informed decision. Please do not allow Glenview's efforts to disrupt this process," the statement continued.